LCI News and Press, Lannett Co Inc From 01/14/20

While using cocaine recreationally remains illegal, the drug does have some use in the medical profession. As it turns out, the Food and Drug Administration (FDA) has approved a nasal spray that contains cocaine as one of its ingredients. Lannett Company (NYSE: LCI) , a small-cap drug manufa...

Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56%  as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...

The FDA has approved Lannett's (NYSE: LCI ) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product. More news on: Lannett Company, Inc., Healthcare stocks news, Stocks on the move, Read more ...

PHILADELPHIA , Jan. 13, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solutio...

Lannett (NYSE: LCI ) has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. More news on: Lannett Company, Inc., Healthcare stocks news, Read more ...

PHILADELPHIA , Jan. 6, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The estimated IQVIA market values of Venlafaxine ER Tablets, ...

Having once traded on the AMEX at $20 per share and viewed as an innovative company with a novel technology designed to aid in developing controlled release and abuse-resistant opioids, the competitive environment dramatically changed for Elite Pharma ( ELTP ). Ultimately, their share price dr...

Lannett (NYSE: LCI )  gains 7.1%  in premarket trading after the FDA approves ANDAs for two dosage strengths of butalbital, acetaminophen, and caffeine capsules. More news on: Lannett Company, Inc., Healthcare stocks news, Stocks on the move, Read more ...

PHILADELPHIA , Dec. 23, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital, Acetaminophen and Caffeine (BAC) Capsules, U...

Healthcare companies filing for mixed shelf offerings: More news on: Lannett Company, Inc., AVROBIO, Inc., UroGen Pharma Ltd., Healthcare stocks news, Read more ...